Related Experiment Video
Updated: Jun 8, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
[Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors]
A Carrato1, C Guillén-Ponce, E Grande-Pulido
1Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, España.
Abstract:
Neutropenia is a frequent adverse event of the pharmacologic treatment of cancer. Morbidity and mortality-associated neutropenia can be successfully treated and prevented with granulocyte-colony stimulating factors (G-CSF). European and American Guidelines recommend their prophylactic use when the expected percentage of febrile neutropenia exceeds 20% or there are concomitant risk factors. Afebrile neutropenia is not considered to benefit from G-CSF treatment. Other approved indications include stem cell mobilization, and an adequate delivery of dose-intense and dose-dense chemotherapy regimens.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
